Long-term survival results of patients with locally advanced gastric cancer and pathological complete response after neoadjuvant chemotherapy and resection

To date, the long-term outcomes of patients with locally advanced gastric cancer (LAGC) who achieved a pathological complete response (pCR) after neoadjuvant therapy are elusive. To evaluate the impact of pCR on the long-term survival of LAGC patients who underwent neoadjuvant therapy and evaluate t...

Full description

Saved in:
Bibliographic Details
Published inTranslational cancer research Vol. 9; no. 2; pp. 529 - 535
Main Authors Wang, Tongbo, Wang, Nianchang, Zhou, Hong, Zhou, Aiping, Jin, Jing, Chen, Yingtai, Zhao, Dongbing
Format Journal Article
LanguageEnglish
Published China AME Publishing Company 01.02.2020
Subjects
Original
locally advanced gastric cancer (LAGC)
postoperative adjuvant chemotherapy
pathological complete response (pCR)
Gastric cancer
neoadjuvant therapy
Online AccessGet full text

Cover

More Information
Summary:To date, the long-term outcomes of patients with locally advanced gastric cancer (LAGC) who achieved a pathological complete response (pCR) after neoadjuvant therapy are elusive. To evaluate the impact of pCR on the long-term survival of LAGC patients who underwent neoadjuvant therapy and evaluate the necessity of postoperative adjuvant chemotherapy. We conducted a retrospective study of clinicopathological and survival data of patients who achieved a pCR after neoadjuvant therapy and resection at the China National Cancer Center between January 2007 and December 2018. Ultimately, 39 patients enrolled in the current study, with a median follow-up time was 30.4 (range 2.5-101.6) months. The 3- and 5-year overall survival (OS) rates were 88.9% and 88.9%, respectively. And the 3- and 5-year disease-free survival (DFS) rates were 88.9% and 88.9%, respectively. During the follow-up, recurrence was observed in 3 patients. Of all 39 patients, 51.3% (n=20) received postoperative adjuvant chemotherapy and 48.7% (n=19) did not. There was no significant difference in OS (P=0.48) and DFS (P=0.47) between patients who underwent postoperative adjuvant chemotherapy and patients who did not. Patients with LAGC who achieved a pCR after neoadjuvant therapy and resection might have a favorable OS and DFS. Our study failed to demonstrate the benefit of adjuvant chemotherapy for those patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Contributions: (I) Conception and design: T Wang, A Zhou, J Jin, Y Chen, D Zhao; (II) Administrative support: Y Chen, D Zhao; (III) Provision of study materials or patients: T Wang, N Wang; (IV) Collection and assembly of data: T Wang, N Wang, H Zhou; (V) Data analysis and interpretation: T Wang, N Wang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
ISSN:2218-676X
2219-6803
DOI:10.21037/tcr.2019.11.37